HBM Holdings Limited
OTC: HBMHF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jingsong Wang
- Employees
- 183
- Headquarters
- Shanghai, China
- IPO year
- 2022
- Market cap
- $1.3B
- Website
- https://www.harbourbiomed.com
Loading HBMHF…
Loading profile data…Frequently asked questions about HBMHF
What does HBM Holdings Limited (HBMHF) do?
HBM Holdings Limited is a biopharmaceutical company in the clinical development phase, dedicated to the discovery and advancement of differentiated antibody therapeutics for immunological and oncological disorders. The firm's robust pipeline includes several notable candidates: Batoclimab (HBM9161), a human monoclonal antibody designed to select...
Where does HBMHF trade?
HBM Holdings Limited (HBMHF) trades on the Other OTC.
What sector is HBMHF in?
HBM Holdings Limited (HBMHF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of HBM Holdings Limited?
Jingsong Wang is the chief executive officer of HBM Holdings Limited (HBMHF).
Where is HBM Holdings Limited headquartered?
HBM Holdings Limited is headquartered in China.
Does HBMHF pay a dividend?
HBM Holdings Limited (HBMHF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did HBMHF go public?
HBM Holdings Limited (HBMHF) completed its initial public offering in 2022.